Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial
Stanley TL, Feldpausch MN, Oh J, et al. (2014). JAMA.
Summary
A single-centre randomised placebo-controlled trial asking whether tesamorelin affects liver fat as well as visceral fat in people with HIV and abdominal fat accumulation. Over six months, visceral adipose tissue and liver fat both fell in the treated group relative to placebo. Fasting glucose was higher in the treated group at two weeks, but the difference was no longer significant at six months. Fifty participants at one hospital, so small; investigator-initiated rather than company-run.